Biotec Pharmacon is a biopharmaceutical company that develops and manufactures new immunomodulatory products and cold adapted marine enzymes. The company focuses on new and effective solutions within wound care, cancer therapies and other immune related disease areas, and aspires to become a leading supplier of novel enzymes for diagnostics and genetic research.

XVIVO Perfusion is a medical technology company which develops and markets solutions and systems for assessing the usability of organs, enabling the treatment of organs and maintaining organs in good condition outside the body pending transplantation.

Chundsell Medicals seeks 20.0 MSEK at a pre‐money valuation of 89.7 MSEK, entailing 18.2% ownership and 16.5% ownership fully diluted. The proceeds are intended to support and accelerate our commercialisation process.

Mass Medical Angels (MA2) is a seed stage investor group exclusively focused on life science and healthcare investments. Our mission is to bring more clinical tools to the marketplace, while attaining superior returns for our investors. To do this, we provide financing and mentoring to early-stage life-science companies so that they can obtain further funding, reach positive cash-flows or get acquired.

HealthCap is a European venture capital firm investing exclusively and globally in life sciences. The investment strategy focuses on diseases with high unmet medical needs and breakthrough therapies that have the potential to be transformative and change medical practice, and the lives of patients suffering these conditions.